24735-18-0 Usage
Description
4-Guanidinobutyl 4-hydroxy-3,5-diMethoxybenzoate hydrochloride is a chemical compound with a unique structure that features a guanidinobutyl group attached to a hydroxy-dimethoxybenzoate moiety. 4-Guanidinobutyl 4-hydroxy-3,5-diMethoxybenzoate hydrochloride is characterized by its hydrochloride salt form, which may contribute to its solubility and reactivity in various chemical and biological processes.
Uses
Used in Pharmaceutical Industry:
4-Guanidinobutyl 4-hydroxy-3,5-diMethoxybenzoate hydrochloride is used as a pharmaceutical agent for the treatment of uterine disorders. It is particularly effective in modifying uterine contractions in rats, which may have implications for the development of treatments for similar conditions in humans.
Used in Research Applications:
Due to its unique structure and properties, 4-Guanidinobutyl 4-hydroxy-3,5-diMethoxybenzoate hydrochloride may also be used in research settings to study the effects of guanidino and hydroxy-dimethoxybenzoate groups on biological systems. This could include investigations into the compound's interactions with proteins, enzymes, or other biomolecules, as well as its potential applications in drug design and development.
Check Digit Verification of cas no
The CAS Registry Mumber 24735-18-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,7,3 and 5 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 24735-18:
(7*2)+(6*4)+(5*7)+(4*3)+(3*5)+(2*1)+(1*8)=110
110 % 10 = 0
So 24735-18-0 is a valid CAS Registry Number.
24735-18-0Relevant articles and documents
Leonurine hydrochloride-a new drug for the treatment of menopausal syndrome: Synthesis, estrogen-like effects and pharmacokinetics
Chen, Guoguang,Ren, Lili,Wang, Jin,Wei, Jie,Zhou, Yaxin
, (2021/12/31)
This research aimed to investigate the estrogen-like effects of Leonurine hydrochloride (Leo). First, we developed a total synthesis of Leo from 3,4,5-trimethoxy-benzoic acid and the structure was confirmed through 1H NMR and mass spectrometry (MS). Then the estrogenic activity of Leo in vitro and in vivo was studied. The proliferation and proliferation inhibitory effects of Leo on MCF-7 cells and MDA-MB-231 cells indicate that Leo exerts estrogen-like effects through estrogen receptor α (ERα) and estrogen receptor β((ERβ) in vitro. Uterotrophic assay in juvenile mice showed that Leo has an estrogen-like effect in vivo, as it can promote the development of the uterus of juvenile mice, increase its uterine coefficient and the size of the uterine cavity, as well as the increased number of uterine glands and the thickened uterine wall. For further research, cyclophosphamide (CTX) was used to establish a mouse model of ovarian function decline. Through this model, we found that Leo can restore the estrous cycle of mice, increase the number of primordial and primary follicles in the ovaries of mice, and regulate the disordered hypothalamic-pituitary-ovarian (HPOA) axis of mice. Finally, the pharmacokinetics of Leo was studied and oral bioavailability of Leo was calculated to be 2.21%. Leo was synthesized and the estrogen-like effect in vitro and in vivo was confirmed as well as its pharmacokinetics.
